-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $865

Benzinga·10/19/2026 16:23:34
Listen to the news
Piper Sandler analyst Biren Amin maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the price target from $854 to $865.